{"filing":{"accession_number":"0001213900-26-068026","cik":"0001739174","ticker":"PHGE","company_name":"BiomX Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"ea0294507-8k_biomx.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390026068026/ea0294507-8k_biomx.htm"},"events":[{"id":5214,"run_id":4567,"accession_number":"0001213900-26-068026","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"BiomX received notice from NYSE Regulation on June 10, 2026 accepting the Company's compliance plan to regain compliance with continued listing standards after failing to maintain required stockholders' equity levels (stockholders' deficit of $1.3 million as of December 31, 2025). The Company has been granted a plan period through September 25, 2027, but faces potential delisting proceedings and a \".BC\" indicator if it fails to regain compliance or make satisfactory progress.","company_name":"BiomX Inc.","ticker":"PHGE","filing_date":"2026-06-12","submitted_at":null,"items":[{"id":6494,"accession_number":"0001213900-26-068026","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"BiomX received notice from NYSE Regulation on June 10, 2026 that it had accepted the Company's compliance plan to regain compliance with continued listing standards. The Company was previously notified on March 25, 2026 that it failed to maintain required stockholders' equity levels under NYSE American rules (Sections 1003(a)(i), (ii), and (iii), citing a stockholders' deficit of $(1,302,000) as of December 31, 2025. While the Company has been granted a plan period through September 25, 2027, the disclosure explicitly warns that failure to regain compliance or make satisfactory progress may result in delisting proceedings, and a \".BC\" (below compliance) indicator will be disseminated with the ticker. This is a material delisting risk event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-12T13:10:07.903448+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6495,"accession_number":"0001213900-26-068026","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.75,"reasoning":"The disclosure references NYSE Regulation's acceptance of \"the plan,\" which in the context of a Regulation FD disclosure strongly suggests acceptance of a listing compliance plan—typically filed when a company has failed to meet continued listing standards. This is a material event affecting the registrant's ability to remain listed on the exchange.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-12T13:10:07.903448+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6494,"accession_number":"0001213900-26-068026","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"BiomX received notice from NYSE Regulation on June 10, 2026 that it had accepted the Company's compliance plan to regain compliance with continued listing standards. The Company was previously notified on March 25, 2026 that it failed to maintain required stockholders' equity levels under NYSE American rules (Sections 1003(a)(i), (ii), and (iii), citing a stockholders' deficit of $(1,302,000) as of December 31, 2025. While the Company has been granted a plan period through September 25, 2027, the disclosure explicitly warns that failure to regain compliance or make satisfactory progress may result in delisting proceedings, and a \".BC\" (below compliance) indicator will be disseminated with the ticker. This is a material delisting risk event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-12T13:10:07.903448+00:00","company_name":"BiomX Inc.","ticker":"PHGE","filing_date":"2026-06-12"},{"id":6495,"accession_number":"0001213900-26-068026","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.75,"reasoning":"The disclosure references NYSE Regulation's acceptance of \"the plan,\" which in the context of a Regulation FD disclosure strongly suggests acceptance of a listing compliance plan—typically filed when a company has failed to meet continued listing standards. This is a material event affecting the registrant's ability to remain listed on the exchange.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-12T13:10:07.903448+00:00","company_name":"BiomX Inc.","ticker":"PHGE","filing_date":"2026-06-12"}]}